MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Consolidator ... Mass Market Scale-up, Global Reach, Public Capital
Consolidators: BioPharmaceuticals
Sanofi-Aventis SA (NYSE: SNY)
Organization & Developments: Sanofi
*Developments: Sanofi
Parents
Organization & Developments: Sanofi
Children
*Dupixent (dupilumab)
2015: Cholesterol drug Praluent approved by FDA
2015: Google Teams Up With Sanofi To Develop Diabetes Tech | Fast Company | Business
2015: Sanofi makes it official--Brandicourt is its man
2015: Sanofi-backed virtual trial gets green light in Europe
2015: Sanofi, Gates Foundation and IDRI team up to improve vaccine development process
2016: Bernie Sanders Slams Drug Price Fixing (LLY, SNY)
2016: Sanofi, Verily eye diabetes jump-start with $500M venture beyond the pill
2017: 'ASCO' Boost For These 2 Small Oncology Plays?...Immune Design (NASDAQ:IMDZ)
2017: VA_65--Sanofi Contract_Effective 9/15/2017 65IB V797D-70230 Effective 9/15/2017
2019: BARDA_Award of a New Task Order for Storage and Stability Testing of Pre-Pandemic Influenza Virus Antigen on behalf of Defense Health Agency
2019: French drugmaker Sanofi, Google to use data tech for innovations
2020: Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion
2020: Sanofi Goes Big on $2 Billion-Plus Vaccine Partnership with Translate Bio
2021: Major Industry Players Partner to Promote Digital Health
2022: Sanofi signs $1.2B pact with Atomwise in latest high-value AI drug discovery deal
2023: ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma, with one med showing 'unprecedented' efficacy
2023: Sanofi Spins Off, Investors Spin Out (Rating Downgrade) (NASDAQ:SNY)
2024: ASPR takes next steps to prepare vaccine against H5 influenza ... ASPR provides approximately $72 million to CSL Seqirus, Sanofi, and GSK to boost U.S. preparedness
2024: BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
2024: Sanofi 2023 Q4 - Results - Earnings Call Presentation
2024: Sanofi breaks into first-line multiple myeloma with FDA approval for Sarclisa
2024: Sanofi: Better Buying Opportunities May Present Themselves In 2024
2024: Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
2024: Sanofi: My Top Pick In Big Pharma
2025: 5 FDA decisions to watch in the first quarter of 2025
Jumps
*Developments: Sanofi (Archives 2009-2014)
*Organization: Sanofi